
Driven by the expansion of aesthetic product sales and the effects of academic marketing, Humedics recorded double-digit growth in both revenue and operating profit for the third quarter of this year. However, net income for the period decreased by 91% compared to the same period last year, reflecting valuation losses on held financial assets.
Humedics announced on the 16th that it recorded consolidated revenue of 50.2 billion won and operating profit of 10 billion won for the third quarter of this year. These figures represent increases of 23% and 11%, respectively, compared to the same period last year. Net income for the same period decreased by 91% to 2.1 billion won.
The revenue increase was driven by factors such as the expanded supply of aesthetic product lines to domestic medical institutions and increased orders for over-the-counter eye drops. The company explained that academic marketing activities, including the 'HART Symposium,' also contributed to the expansion of product sales. Operating profit also rose due to improved gross profit from increased sales and orders for aesthetic products.
Humedics plans to continue securing new customers centered on its aesthetic product line in the fourth quarter as well. The company is pushing to expand sales of skin booster 'Elleve Balance,' poly-D, L-lactic acid (PDLLA)-based 'Estefil' and 'Estefil Luxe,' medical device 'Dermashine Duo_RF,' wound dressing 'Arche,' and plant-derived exosome 'Ezment.'
Along with this, the company is expanding domestic and international online and offline distribution networks for Elleve cosmetic products and pursuing additional contract manufacturing (CMO) orders through diversification of prescription drug items.
The company is also promoting the strengthening of its marketing capabilities through the inclusion of a new subsidiary. In September last month, Humedics acquired 51% of the shares in Clacorp, an influencer marketing and data-based marketing platform company, and included it as a consolidated subsidiary starting from the third quarter.
Clacorp is a company that operates influencer marketing campaigns and possesses artificial intelligence (AI)-based data analysis technology. Humedics plans to leverage this to strengthen the digital marketing competitiveness of its group's key businesses, including aesthetic medicine, cosmetics, and health functional foods.
The company will also continue its shareholder return policy. At a board meeting on the 12th last month, Humedics decided to pay a third-quarter dividend of 200 won per share. The record date for the dividend is December 4. In accordance with its medium- and long-term dividend policy, the company plans to increase the annual dividend per share by 5% to 30% through 2028. This dividend will be conducted as a reduced dividend through the reduction of capital reserves.
Kang Min-jong, CEO of Humedics, stated, "We will gradually expand our market share both domestically and internationally based on portfolio diversification tailored to aesthetic market demand, as well as safety and quality competitiveness." He added, "We will strengthen our global market competitiveness through continuous investment in research and development costs, production facilities, and personnel."